Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Alexander Bennett, Clara K. Chow, Michael Chou, Hakim Moulay Dehbi, Ruth Webster, Abdul Salam, Anushka Patel, Bruce Neal, David Peiris, Jay Thakkar, John Chalmers, Mark Nelson, Christopher Reid, Graham S. Hillis, Mark Woodward, Sarah Hilmer, Tim Usherwood, Simon Thom, Anthony Rodgers

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, therefore, conducted a systematic review and meta-analysis of randomized controlled trials with at least one quarter-dose and one placebo and standard-dose monotherapy arm. A search was conducted of Medline, Embase, Cochrane Registry, Food and Drug Administration, and European Medicinal Agency websites. Data on blood pressure and adverse events were pooled using a fixed-effect model, and bias was assessed using Cochrane risk of bias. The review included 42 trials involving 20 284 participants. Thirty-six comparisons evaluated quarter-dose with placebo and indicated a blood pressure reduction of -4.7/-2.4 mm Hg (P<0.001). Six comparisons were of dual quarter-dose therapy versus placebo, observing a -6.7/ -4.4 mm Hg (P<0.001) blood pressure reduction. There were no trials of triple quarter-dose combination versus placebo, but one quadruple quarter-dose study observed a blood pressure reduction of -22.4/-13.1 mm Hg versus placebo (P<0.001). Compared with standard-dose monotherapy, the blood pressure differences achieved by single (37 comparisons), dual (7 comparisons), and quadruple (1 trial) quarter-dose combinations were +3.7/+2.6 (P<0.001), +1.3/-0.3 (NS), and -13.1/-7.9 (P<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.

Original languageEnglish
Pages (from-to)85-93
Number of pages9
JournalHypertension
Volume70
Issue number1
DOIs
Publication statusPublished - 1 Jul 2017

Fingerprint

Meta-Analysis
Randomized Controlled Trials
Blood Pressure
Safety
Placebos
United States Food and Drug Administration
Therapeutics
Registries

Cite this

Bennett, Alexander ; Chow, Clara K. ; Chou, Michael ; Dehbi, Hakim Moulay ; Webster, Ruth ; Salam, Abdul ; Patel, Anushka ; Neal, Bruce ; Peiris, David ; Thakkar, Jay ; Chalmers, John ; Nelson, Mark ; Reid, Christopher ; Hillis, Graham S. ; Woodward, Mark ; Hilmer, Sarah ; Usherwood, Tim ; Thom, Simon ; Rodgers, Anthony. / Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. In: Hypertension. 2017 ; Vol. 70, No. 1. pp. 85-93.
@article{c44c414cf7a64a00bbd99d162a33423d,
title = "Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials",
abstract = "There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, therefore, conducted a systematic review and meta-analysis of randomized controlled trials with at least one quarter-dose and one placebo and standard-dose monotherapy arm. A search was conducted of Medline, Embase, Cochrane Registry, Food and Drug Administration, and European Medicinal Agency websites. Data on blood pressure and adverse events were pooled using a fixed-effect model, and bias was assessed using Cochrane risk of bias. The review included 42 trials involving 20 284 participants. Thirty-six comparisons evaluated quarter-dose with placebo and indicated a blood pressure reduction of -4.7/-2.4 mm Hg (P<0.001). Six comparisons were of dual quarter-dose therapy versus placebo, observing a -6.7/ -4.4 mm Hg (P<0.001) blood pressure reduction. There were no trials of triple quarter-dose combination versus placebo, but one quadruple quarter-dose study observed a blood pressure reduction of -22.4/-13.1 mm Hg versus placebo (P<0.001). Compared with standard-dose monotherapy, the blood pressure differences achieved by single (37 comparisons), dual (7 comparisons), and quadruple (1 trial) quarter-dose combinations were +3.7/+2.6 (P<0.001), +1.3/-0.3 (NS), and -13.1/-7.9 (P<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.",
keywords = "blood pressure, hypertension, meta-analysis, pharmacology, safety",
author = "Alexander Bennett and Chow, {Clara K.} and Michael Chou and Dehbi, {Hakim Moulay} and Ruth Webster and Abdul Salam and Anushka Patel and Bruce Neal and David Peiris and Jay Thakkar and John Chalmers and Mark Nelson and Christopher Reid and Hillis, {Graham S.} and Mark Woodward and Sarah Hilmer and Tim Usherwood and Simon Thom and Anthony Rodgers",
year = "2017",
month = "7",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.117.09202",
language = "English",
volume = "70",
pages = "85--93",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

Bennett, A, Chow, CK, Chou, M, Dehbi, HM, Webster, R, Salam, A, Patel, A, Neal, B, Peiris, D, Thakkar, J, Chalmers, J, Nelson, M, Reid, C, Hillis, GS, Woodward, M, Hilmer, S, Usherwood, T, Thom, S & Rodgers, A 2017, 'Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials' Hypertension, vol. 70, no. 1, pp. 85-93. https://doi.org/10.1161/HYPERTENSIONAHA.117.09202

Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. / Bennett, Alexander; Chow, Clara K.; Chou, Michael; Dehbi, Hakim Moulay; Webster, Ruth; Salam, Abdul; Patel, Anushka; Neal, Bruce; Peiris, David; Thakkar, Jay; Chalmers, John; Nelson, Mark; Reid, Christopher; Hillis, Graham S.; Woodward, Mark; Hilmer, Sarah; Usherwood, Tim; Thom, Simon; Rodgers, Anthony.

In: Hypertension, Vol. 70, No. 1, 01.07.2017, p. 85-93.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents

T2 - A Systematic Review and Meta-Analysis of Randomized Controlled Trials

AU - Bennett, Alexander

AU - Chow, Clara K.

AU - Chou, Michael

AU - Dehbi, Hakim Moulay

AU - Webster, Ruth

AU - Salam, Abdul

AU - Patel, Anushka

AU - Neal, Bruce

AU - Peiris, David

AU - Thakkar, Jay

AU - Chalmers, John

AU - Nelson, Mark

AU - Reid, Christopher

AU - Hillis, Graham S.

AU - Woodward, Mark

AU - Hilmer, Sarah

AU - Usherwood, Tim

AU - Thom, Simon

AU - Rodgers, Anthony

PY - 2017/7/1

Y1 - 2017/7/1

N2 - There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, therefore, conducted a systematic review and meta-analysis of randomized controlled trials with at least one quarter-dose and one placebo and standard-dose monotherapy arm. A search was conducted of Medline, Embase, Cochrane Registry, Food and Drug Administration, and European Medicinal Agency websites. Data on blood pressure and adverse events were pooled using a fixed-effect model, and bias was assessed using Cochrane risk of bias. The review included 42 trials involving 20 284 participants. Thirty-six comparisons evaluated quarter-dose with placebo and indicated a blood pressure reduction of -4.7/-2.4 mm Hg (P<0.001). Six comparisons were of dual quarter-dose therapy versus placebo, observing a -6.7/ -4.4 mm Hg (P<0.001) blood pressure reduction. There were no trials of triple quarter-dose combination versus placebo, but one quadruple quarter-dose study observed a blood pressure reduction of -22.4/-13.1 mm Hg versus placebo (P<0.001). Compared with standard-dose monotherapy, the blood pressure differences achieved by single (37 comparisons), dual (7 comparisons), and quadruple (1 trial) quarter-dose combinations were +3.7/+2.6 (P<0.001), +1.3/-0.3 (NS), and -13.1/-7.9 (P<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.

AB - There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, therefore, conducted a systematic review and meta-analysis of randomized controlled trials with at least one quarter-dose and one placebo and standard-dose monotherapy arm. A search was conducted of Medline, Embase, Cochrane Registry, Food and Drug Administration, and European Medicinal Agency websites. Data on blood pressure and adverse events were pooled using a fixed-effect model, and bias was assessed using Cochrane risk of bias. The review included 42 trials involving 20 284 participants. Thirty-six comparisons evaluated quarter-dose with placebo and indicated a blood pressure reduction of -4.7/-2.4 mm Hg (P<0.001). Six comparisons were of dual quarter-dose therapy versus placebo, observing a -6.7/ -4.4 mm Hg (P<0.001) blood pressure reduction. There were no trials of triple quarter-dose combination versus placebo, but one quadruple quarter-dose study observed a blood pressure reduction of -22.4/-13.1 mm Hg versus placebo (P<0.001). Compared with standard-dose monotherapy, the blood pressure differences achieved by single (37 comparisons), dual (7 comparisons), and quadruple (1 trial) quarter-dose combinations were +3.7/+2.6 (P<0.001), +1.3/-0.3 (NS), and -13.1/-7.9 (P<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.

KW - blood pressure

KW - hypertension

KW - meta-analysis

KW - pharmacology

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85020156851&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.117.09202

DO - 10.1161/HYPERTENSIONAHA.117.09202

M3 - Review article

VL - 70

SP - 85

EP - 93

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -